Issues
-
Cover Image
Cover Image
The risk and prognosis of Acute Promyelocytic Leukemia (APL) are notably heightened in individuals who are overweight or obese, yet the exact molecular mechanism responsible remains unclear. In the study starting on page 59, Mazzarella and colleagues confirmed that obesity induced by a high-fat diet led to leukemogenesis in validated mouse APL models (Ctsg-PML::RARA), shedding light on a potential molecular mechanism. The cover image is adapted from Figure 6G, which illustrates that the presence of the oncogene PML::RARA, in conjunction with the polyunsaturated fatty acid Linoleic acid, induces the translocation of the transcription factor PPARδ into the nucleus. The translocation of PPARδ between the nucleus and cytoplasm was assessed through immunofluorescence staining with a PPARδ antibody (green), DAPI (blue) for the nucleus, and phalloidin (red) to highlight the F-actin structure. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
Highlights from the Literature
Spotlight
Research Brief
Acceptability of Personalized Lung Cancer Screening Program Among Primary Care Providers
Personalized LCS facilitated by a risk model and/or a biomarker test is proposed as an alternative to existing programs. Acceptability of personalized approach among PCPs is unknown. The goal of this study is to assess the acceptability of personalized LCS among PCPs.
Research Articles
High-Fat Diet Promotes Acute Promyelocytic Leukemia through PPARδ-Enhanced Self-renewal of Preleukemic Progenitors
Our work informs interventions aimed at counteracting the cancer-promoting effect of obesity. On the basis of our study, individuals with a history of chronic obesity may still significantly reduce their risk by switching to a healthier lifestyle, a concept supported by evidence in solid tumors but not yet in hematologic malignancies.
Breast Cancer Polygenic-Risk Score Influence on Risk-Reducing Endocrine Therapy Use: Genetic Risk Estimate (GENRE) Trial 1-Year and 2-Year Follow-Up
Risk-reducing medications for breast cancer are considerably underused. Informing women at risk with precise and individualized risk assessment tools may substantially affect the incidence of breast cancer. In our study, a risk assessment tool (IBIS-polygenic-risk score) yielded promising results, with 39% of women at highest risk starting preventive medication.
Letter to the Editor
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.